Pax Medica, Inc. PXMD
We take great care to ensure that the data presented and summarized in this overview for PaxMedica, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PXMD
Top Purchases
Top Sells
About PXMD
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Insider Transactions at PXMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2024
|
Stephen Sheldon CFO and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,356
-24.87%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
Howard J. Weisman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,927
-7.77%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
Charles J Casamento Director |
SELL
Payment of exercise price or tax liability
|
Direct |
992
-29.37%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
John F Coelho Director |
SELL
Payment of exercise price or tax liability
|
Direct |
207
-4.49%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
David W. Hough Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,452
-19.74%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
Karen La Rochelle Director |
SELL
Payment of exercise price or tax liability
|
Direct |
604
-21.35%
|
$0
$0.69 P/Share
|
|
Mar 12
2024
|
Zachary Rome Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,904
-32.37%
|
$0
$0.69 P/Share
|
|
Feb 21
2024
|
Stephen Sheldon CFO and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
243
-1.77%
|
$0
$0.66 P/Share
|
|
Feb 21
2024
|
David W. Hough Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
291
-3.8%
|
$0
$0.66 P/Share
|
|
Jan 29
2024
|
Zachary Rome Director |
SELL
Open market or private sale
|
Direct |
811
-5.08%
|
$0
$0.48 P/Share
|
|
Jan 29
2024
|
Howard J. Weisman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
372
-0.98%
|
$0
$0.47 P/Share
|
|
Jan 29
2024
|
Charles J Casamento Director |
SELL
Payment of exercise price or tax liability
|
Direct |
97
-2.79%
|
$0
$0.76 P/Share
|
|
Jan 29
2024
|
John F Coelho Director |
SELL
Open market or private sale
|
Direct |
27
-0.58%
|
$0
$0.48 P/Share
|
|
Jan 29
2024
|
Karen La Rochelle Director |
SELL
Open market or private sale
|
Direct |
78
-2.68%
|
$0
$0.48 P/Share
|
|
Nov 27
2023
|
Zachary Rome Director |
SELL
Open market or private sale
|
Direct |
359
-2.2%
|
$359
$1.03 P/Share
|
|
Nov 27
2023
|
Karen La Rochelle Director |
SELL
Open market or private sale
|
Direct |
35
-1.19%
|
$35
$1.03 P/Share
|
|
Nov 27
2023
|
Michael Derby > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
185
-0.72%
|
$185
$1.03 P/Share
|
|
Nov 27
2023
|
Howard J. Weisman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
162
-0.42%
|
$162
$1.03 P/Share
|
|
Nov 27
2023
|
John F Coelho Director |
SELL
Open market or private sale
|
Direct |
12
-0.26%
|
$12
$1.02 P/Share
|
|
Nov 20
2023
|
Stephen Sheldon CFO and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
971
-6.6%
|
$971
$1.75 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 100K shares |
|---|
| Open market or private sale | 37.8K shares |
|---|---|
| Payment of exercise price or tax liability | 22.6K shares |